Bucillamine

DRUG5 trials

Sponsors

Saitama Medical University, Revive Therapeutics, Ltd., Sanofi

Conditions

Covid19CystinuriaGoutRheumatoid Arthritis

Phase 2

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

CompletedNCT02330796

Revive Therapeutics, Ltd.Gout

Start: 2015-04-30End: 2015-11-30Updated: 2016-10-05

Bucillamine Phase 2 Trial in Patients With Cystinuria

Revive Therapeutics, Ltd.Cystinuria

Start: 2017-05-01End: 2018-03-31Target: 30Updated: 2017-05-18

Phase 3

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

CompletedNCT02373202

SanofiRheumatoid Arthritis

Start: 2015-02-28End: 2016-11-30Updated: 2018-01-30

Bucillamine in Treatment of Patients With COVID-19

TerminatedNCT04504734

Revive Therapeutics, Ltd.Covid19

Start: 2020-11-27End: 2023-06-12Updated: 2023-07-07

Phase 4

Bucillamine Study of Holding Remission After Infliximab Dose-off

Saitama Medical UniversityRheumatoid Arthritis

Start: 2007-01-31Target: 40Updated: 2011-01-05

Related Papers

Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trials

Modern Rheumatology2024-07-282 citations

The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: A post-hoc analysis of the HARUKA phase 3 study

Modern Rheumatology2024-07-271 citations

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

Modern Rheumatology2019-07-0328 citations